Your session is about to expire
← Back to Search
Cytokine
An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
Phase 3
Waitlist Available
Research Sponsored by Orasis Pharmaceuticals Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Subjects must have presbyopia
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
Summary
This trial is testing the safety of a new treatment called CSF-1 for people who have trouble seeing things up close due to aging. The study will compare CSF-1 to another treatment over a period of time.
Eligible Conditions
- Presbyopia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2022 Phase 3 trial • 309 Patients • NCT045999336%
instillation site pain
5%
headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
CSF-1
Vehicle
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: CSF-1Experimental Treatment1 Intervention
One drop bilaterally twice daily for approximately 6 weeks
Group II: VehiclePlacebo Group1 Intervention
One drop bilaterally twice daily for approximately 6 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CSF-1
2022
Completed Phase 3
~960
Find a Location
Who is running the clinical trial?
Orasis Pharmaceuticals Ltd.Lead Sponsor
5 Previous Clinical Trials
851 Total Patients Enrolled
5 Trials studying Presbyopia
851 Patients Enrolled for Presbyopia